Features of Protease Inhibitor Mini Tablets:• Improved formulation—tablets dissolve quickly to form a clear solution• Economical—more cost effective than other commercially available formulations for equivalent volumes• Convenient—ready-to-use, fully disclosed, broad-spectrum formulations• Compatible—use directly with Pierce BCA assays

Pierce Protease Inhibitor Mini Tablets protect proteins from proteolytic degradation through inhibition of the serine proteases, cysteine proteases, aspartic acid proteases, and aminopeptidases that are typically present in cell lysate samples. The tablets contain AEBSF, aprotinin, bestatin, E-64, leupeptin, and pepstatin A. Stable for storage at 4°C for up to 12 months, each mini tablet is sufficient for 10 mL of solution, and is suitable for reagent preparation prior to protein extraction from tissue and cultured cells.

Proteases make up a large category of enzymes, including endopeptidases and exopeptidases, which catalyze the hydrolytic breakdown of proteins into peptides or amino acids. Proteases reside in cellular compartments, but upon cell lysis the proteases are released, resulting in the degradation of valuable proteins. For this reason, it is common practice to add multiple compounds known to inactivate or inhibit proteases to cell lysis buffers or cell extracts.

To use Pierce Protease Inhibitor Mini Tablets, simply dissolve 1 tablet in 10 mL of buffer or lysate. The protease inhibitor formulation is compatible with most detergent-based cell lysis reagents, including Pierce Cell Lysis solutions. Pierce Protease Inhibitor Mini Tablets do not contain phosphatase inhibitors. If necessary, phosphatase inhibitors, such as Pierce Phosphatase Inhibitor Mini Tablets, can be added along with the protease inhibitor tablets.

Related productsPierce Protease Inhibitor Mini Tablets, EDTA-freePierce Protease Inhibitor TabletsPierce Phosphatase Inhibitor Mini TabletsPierce Protease and Phosphatase Inhibitor Mini Tablets